BRAF and melanoma: In the context of personalized therapy, biomarkers have a prognostic role but are also predictive in assessing the therapeutic response, allowing the selection of patients most likely to respond to a specific treatment, integrating both sensitivity and resistance to various target therapies (e.g., BRAF V600 mutated malignant melanoma is highly sensitive to Vemurafenib therapy, while the “wild” variant is resistance to this therapy).